Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03590678 · ClinicalTrials.gov registry record
Collection of Whole Blood Specimens in Pregnant Women
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 3,000
- Enrollment target
NCT03590678: Completed study, sponsored by Illumina.
NCT03590678 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 3,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03590678 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 3,000 participants
- Enrollment target
Study Summary
To prospectively collect whole blood specimens and clinical data from pregnant women scheduled for an invasive prenatal diagnostic procedure ("invasive procedure"). Specimens will be used for future testing with an investigational NIPT.
Primary Outcome
To collect maternal whole blood specimens from approximately 5,150 women with corresponding cytogenetic results from invasive prenatal diagnostic procedures (performed per the standard of care) to achieve sample size goals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2019-12-31 |
What the finished NCT03590678 record still lists
NCT03590678 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03590678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03590678 about?
NCT03590678 is a clinical study titled "Collection of Whole Blood Specimens in Pregnant Women". To prospectively collect whole blood specimens and clinical data from pregnant women scheduled for an invasive prenatal diagnostic procedure ("invasive procedure"). Specimens will be used for future testing with an investigational NIPT.
What is the current status of trial NCT03590678?
This trial is currently completed. The enrollment target is 3,000 participants. The study started on 2017-02-13. Estimated completion is 2019-12-31.
Who is sponsoring clinical trial NCT03590678?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI